News

As Glucose Levels Fall in the Brain, Series of Molecular Reactions Seen to Kill Neurons

Low glucose levels in the brain are known to lead memory problems and cognitive decline, and new research suggests they do so by triggering a series of molecular reactions that ultimately kill neurons. These findings provide fresh insight into changes that set the stage for Alzheimer’s disease. The research also identified a protein that appears…

Neuronascent Granted Third US Patent for Potential Methods to Treat Alzheimer’s, Other Disorders

Neuronascent has been issued a U.S. patent for methods of stimulating neurogenesis and/or inhibiting neuronal degeneration that have potential therapeutic applications in Alzheimer’s disease, Parkinson’s disease, post-traumatic stress disorder, depression, and other psychiatric disorders. The biopharma Neuronascent discovers and develops novel therapeutics aimed at halting or reversing neurological disorders. The…

Georgetown to Lead Phase 2 Study of Cancer Drug in Treating Alzheimer’s

Researchers at Georgetown University Medical Center (GUMC) are recruiting participants for a clinical trial to evaluate the cancer drug Tasigna (nilotinib) in people with mild to moderate Alzheimer’s disease (AD). The randomized, double-blind, placebo-controlled Phase 2 clinical trial (NCT02947893) will evaluate how low doses of Tasigna impact safety, biomarkers, and…